Faron Pharmaceuticals Ltd., of Turku, Finland, enrolled the first patient in the phase III INTEREST clinical program for Traumakine for the treatment of acute respiratory distress syndrome. Read More
Anavex Life Sciences Corp., of New York, reported in its 10-K filing that it had received a subpoena from the SEC on Dec. 22, which indicates that the agency is conducting a formal investigation. Read More
LONDON – Synthetic promoters – a new and controllable means of directing gene expression – are starting to be deployed to increase the potency and specificity of gene therapies and to boost yields in bioprocessing. Read More
BOGOTA, Colombia – Brazilian pharma major Eurofarma is looking to expand its footprint by tapping into markets in Africa, investing in the U.S. and reaching deeper into Latin America markets through new plants, the acquisition of established businesses and by introducing new products. Read More
Since the 1970s, acute myeloid leukemia (AML) subtypes have been classified by cellular variances under the microscope. In recent times, however, it has been discovered that AML's heterogeneity lies within the chromosomes as well. As an increasing amount of the disease's genetic variances are being discovered, it is clear that they have a significant prognostic effect on treatment response. Read More
The long-planned debut of Aralez Pharmaceuticals Inc., a Toronto-based company conceived by specialty pharma veteran Adrian Adams as a profitable and tax-advantaged combination of Pozen Inc. and Tribute Pharmaceuticals Canada Inc., moved closer to finality this week with the successful registration of Aralez shares on Nasdaq and the ironing out of an aspirin supply issue that has weighed on the company since 2014. Read More
SHANGHAI – Wuxi Healthcare Ventures closed a fundraising round at $290 million – attracting almost 50 percent more capital than was initially sought – and will now get back to the business of continuing the investment strategy developed with its first fund: find in the U.S,, build in China. Read More
While Congress, health care number crunchers and biosimilar makers are chomping at the bit for the FDA to hurry up already and spur interchangeability guidance out of the gate, Abbvie Inc. is, not surprisingly, saying "whoaaa." Read More
